Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Am J Gastroenterol. 2022 Jan 1;117(1):158-166. doi: 10.14309/ajg.0000000000001543.
Statin use has been examined as a potential chemopreventive strategy against colorectal cancer (CRC). Previous studies have not been able to investigate this topic with adequate follow-up time or disentangle the effects of statin use and total cholesterol level. We investigated prospectively this topic.
Eligible participants (100,300 women and 47,991 men) in the Nurses' Health Study and Health Professionals Follow-Up Study were followed for up to 24 years. Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals.
We documented 2,924 incident CRC cases during follow-up. In fully adjusted analyses, longer duration of statin use was associated with higher risk of colon cancer (hazard ratios, the 95% confidence interval was 1.09, 0.95-1.25 for 1-5 years; 1.16, 0.99-1.36 for 6-10 years; 1.08, 0.81-1.44 for 11-15 years; 1.85, 1.30-2.61 for >15 years; vs never users, P = 0.004 for trend) rather than rectal cancer. The risk elevation was driven by proximal colon cancer (1.16, 0.98-1.38 for 1-5 years; 1.19, 0.98-1.45 for 6-10 years; 1.25, 0.89-1.74 for 11-15 years; 2.17, 1.46-3.24 for >15 years; vs never users, P = 0.001 for trend) rather than distal colon cancer. The results remained robust in analyses among participants with hypercholesterolemia or who never received screening. Total cholesterol level was not associated with CRC risk.
This study does not support benefit of statin use in CRC chemoprevention or any association between total cholesterol level and CRC risk. On the contrary, long-term statin use may be associated with increased colon cancer risk (driven by proximal colon cancer).
他汀类药物的使用已被研究作为预防结直肠癌(CRC)的潜在化学预防策略。以前的研究未能在足够的随访时间内或在不区分他汀类药物使用和总胆固醇水平的情况下研究这个课题。我们前瞻性地研究了这个课题。
符合条件的参与者(100300 名女性和 47991 名男性)参加了护士健康研究和健康专业人员随访研究,随访时间长达 24 年。使用 Cox 比例风险模型估计风险比和 95%置信区间。
在随访期间,我们记录了 2924 例 CRC 病例。在完全调整的分析中,他汀类药物使用时间较长与结肠癌风险增加相关(风险比,95%置信区间为 1.09,0.95-1.25 为 1-5 年;1.16,0.99-1.36 为 6-10 年;1.08,0.81-1.44 为 11-15 年;1.85,1.30-2.61 年;与从不使用者相比,P = 0.004 趋势)而不是直肠癌。这种风险升高是由近端结肠癌驱动的(1.16,0.98-1.38 为 1-5 年;1.19,0.98-1.45 为 6-10 年;1.25,0.89-1.74 年;11-15 年;2.17,1.46-3.24 年;与从不使用者相比,P = 0.001 趋势)而不是远端结肠癌。在患有高胆固醇血症或从未接受过筛查的参与者中,分析结果仍然稳健。总胆固醇水平与 CRC 风险无关。
本研究不支持他汀类药物在 CRC 化学预防中的益处,也不支持总胆固醇水平与 CRC 风险之间的任何关联。相反,长期使用他汀类药物可能与结肠癌风险增加相关(由近端结肠癌驱动)。